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Background: Chlamydia trachomatis interaction with HR-HPV types has highlighted a central role in cervical cancer
development. The aim of this study was to investigate HPV prevalence and genotypes distribution in women at risk
for C. trachomatis infection and negative for intraepithelial lesion or malignancy.
Methods: 1071 cervical swabs were tested for C. trachomatis by Real Time PCR and genotyping by ompA gene
sequencing. Additionally, a quantitative Real time-PCR was performed to assess the expression of the C. trachomatis
Hsp60–encoding gene (Ct604 portion), linked to a persistent status of infection. HPV infection and genotypes was
investigated in C. trachomatis positive women using Luminex technology.
Results: C. trachomatis infection was detected in 53 out of 1071 (4.5%) samples, of which the 53% resulted positive
for Hsp60 gene expression. The overall prevalence of HPV infection in C. trachomatis positive samples was of 60.4%
(32/53): in 37.5% of samples was present a single genotype, while multiple genotypes infections were found in the
62.5% of them. Among women with a C. trachomatis chronic infection, 68% were HPV co-infected and the 79%
showed multiple genotypes. Should be noted that levels of C. trachomatis Hsp60 expression in HPV co-infected
women were significantly lower compared to women infected only with C. trachomatis. The C. trachomatis serotype
F was found in the majority of samples, independently of HPV infection.
Conclusions: A high prevalence of HPV multiple infections have been found in young women affected with a C.
trachomatis chronic infection. These observations suggested that the expression of CHSP60-1, interfering with both
apoptotic and cellular senescence pathways, may promote a favourable local microenvironment for HPV infection.
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Chlamydia trachomatis (C. trachomatis), an intracellular
bacteria characterized by a unique biphasic developmental
cycle, is the most common sexually transmitted pathogens
in women. Although C. trachomatis can cause pelvic in-
flammatory disease (PID), infertility, ectopic pregnancy,
the clinical course is usually sub-acute and poorly* Correspondence: manola.comar@burlo.trieste.it
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unless otherwise stated.symptomatic and the microorganism is rarely detected in
subjects without clinical signs of infection [1].
The ability of C. trachomatis to cause chronic persistent
infection, characterized by the permanence of microorgan-
isms in the host cells, can represent a common event [2].
During persistent status, C. trachomatis produces a large
quantity of Heat shock protein 60 (Hsp60) exhibited on the
host cell surface and released into the extracellular space
and in the bloodstream. This protein is considered a useful
marker during clinical complications since its expression
induce host chronic inflammation response [1,3,4]. Thus,
this microorganism is considered as a potent immunogen,
stimulating a rapid and intense inflammatory response in-
volving previously sensitized lymphocytes [5].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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consistent evidence about a real implication of C. tra-
chomatis in cervical cancer, the co-infection with
Human papillomavirus (HPV), sharing the transmis-
sion route and the same risk factors, have recently
highlighted [6-8]. A role for C. trachomatis as cofactor
was suggested, since it seems to facilitate the penetra-
tion of HPV and the progress of cervical lesions inter-
fering in the immunological response [9]. Moreover,
some authors recently detected a high-risk for the de-
velopment of cervical cancer in patients with HPV
infection and history of C. trachomatis [10]. Neverthe-
less, the prevalence and distribution of HPV genotypes
associated to C. trachomatis infection and its clinical
persistence are poorly explored.
HPVs are a family of DNA viruses that infect cutane-
ous epithelia, oral and genital mucosa. More than 100
different HPV types have been identified and charac-
terized in two risk classes on the basis of their onco-
genic potential: Low-risk (LR-HPV) types associated
with benign genital warts and High-risk (HR-HPV)
type considered the etiological agents of cervical can-
cer and other genital malignancies [11]. Approximately
15 HR-HPV genotypes are clearly associated with cer-
vical cancer of which HPV16 and HPV18 are the most
carcinogenic, since they are responsible for approxi-
mately 50% and 20% of all cervical cancers worldwide,
respectively. Multiple human papillomavirus genotypes
often coexist within cervical epithelia and are fre-
quently detected together in women with precancer
cervical lesions [12]. Nevertheless, although HPV is a
prerequisite for cervical cancer only a small number of
women exposed to this virus developed cancer, imply-
ing that other risk factors may be considered as cofac-
tors rather than independent factors. On this basis, the
characterization of HPV infection in women suffering
from C. trachomatis could be important in generating
hypotheses regarding the possible synergism of these
pathogens in cervical malignancy [13-16].
The aim of this study was to investigate HPV geno-
types distribution and the frequency of infection in
Italian women considered at risk for C. trachomatis in-
fection but negative for cervical lesions or malignancy.
Furthermore, the role of C. trachomatis chronic infection
in promoting HPV susceptibility has been evaluated.
Methods
Specimens
In 2013 year, cervical swabs (CS) specimen from 1071
women at risk for C. trachomatis infection were col-
lected at the Virology laboratory of the IRCCS-Burlo
Garofolo of Trieste, Italy, as part of C. trachomatis rou-
tine screening practices. Cervical samples were collected
using a 200 mm polyethylene Cervex brush device(Rovers Medical Devices B.V., The Netherlands) in
500 μl of TE buffer. The study was approved by the
Institutional Scientific Board of the Institute for Mater-
nal and Child Health - IRCCS “Burlo Garofolo”–Trieste,
Italy and informed consent was obtained from each par-
ticipant in accordance with the principles outlined in the
Declaration of Helsinki.
C. trachomatis detection
Genomic DNA was extracted, after samples centrifuga-
tion, using the QIAamp DNA Blood miniKit (Qiagen,
GmbH, Germany) as indicated by the supplier, and then
stored at −80°C until analysis.
The presence of C. trachomatis DNA was detected by
Real Time PCR (RT-PCR), using a commercial kit
(CTDNA, Dia.Pro, Italia), detection limit of the assay was 1
copies/μl, to amplify a conserved region of the cryptic plas-
mid element of C. trachomatis, following recommended
protocol. The amplification and PCR product detection
were performed with the ABI Prism 7900 Sequence Detec-
tion system (Applied Biosystems, Italy).
HSp60 gene expression
C. trachomatis -RNA extraction and cDNA synthesis
An aliquot, from each CS fresh specimen (1 ml), was
centrifuged at 14.000 rpm for 15 min at 4°C and total
RNA was extracted to the pellet obtained by RNeasy
Mini kit (Qiagen GmbH, Hilden, Germany) in according
to the manufacturer’s instructions. The RNA final concen-
tration (25 μg/ml) eluted in 50 μl of distilled water, was
treated during sample processing with Dnase I (RNase-
Free DNase Set, Qiagen GmbH, Hilden, Germany), and
subsequently stored at −80, in order to avoid DNA gen-
omic contaminations.
cDNA synthesis was performed using kit SuperScript
VILO™ cDNA Synthesis Kit (Invitrogen, Carlsbad, CA,
USA), according to manufacturer’s instructions. Briefly,
14 μl of RNA were added to a mixture containing: 5X
VILO™ Reaction Mix10, 10X Superscript Enzyme Mix
and diethyl-pyro carbonate water (DEPC-treated) until
a final volume of 20 μl and subsequently incubated at
42°C for 60 minutes and then at 85°C for 5 minutes.
cDNA synthesized was employed for quantitative RT-
PCR (qPCR).C. trachomatis-Hsp60 qPCR
To quantify the transcript level for the C. trachomatis
portion Hsp60 gene (Ct604) in specimen, a dedicated
qPCR was used as previously described [17,18]. The
sensitivity of each assay was determined to be the lowest
dilution of DNA (2 10−4 ng/ml corresponding to one gen-
ome copies/μl) and a standard curve equations were used
to calculate the absolute copy number of gene mRNA.
Table 1 Prevalence of CT distribution in women at risk of
infection by clinical department and mean age
Clinical Department n° women Mean Age ± ơ CT n° + (%)
Outpatients 829 35 ± 10 29 (3.5%)
STI 161 30 ± 10 20 (12.4%)
ART 81 37 ± 10 4 (4.9%)
Total 1071 35 ± 10 53 (4.5%)
STI: Sexually Transmitted Infection; ART: Assisted Reproductive Technology;
CT: C. trachomatis.
Table 2 HPV co-infection distribution in women with
CT infection




N° N°POS/TOT N°POS/TOT N°POS/TOT
(%) (%) (%)
53 32/53 12/53 20/53
(60.4) (22.6) (37.7)
*(from 2- to 8 genotypes); CT: C. trachomatis; HPV: Human papillomavirus.
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negative control with PCR-grade water and a positive
control (C. trachomatis strain-TW-3). PCR reaction, in a
final volume of 20 μl, contained: 5 μl of cDNA, 2 μl LC
FastStart DNA Master SYBR Green I (Roche Molecular
Biochemicals, Germany), 5 mM MgCl2 and 0.8 μM each
primer. The thermocycling condition was: 95°C at
10 min followed by 40 cycles of 15 s at 95°C and 1 min
at 63°C. The amplification was carried out in an ABI
7900HT Fast Real Time PCR System (Applied Biosys-
tems, Italy). The concentration of unknown samples
based on their Ct values was determined with analytical
software (Software SDS 2.4; Applied Biosystems) [19].
The specificity of qPCR was further confirmed by agar-
ose gel electrophoresis analysis, which showed the ex-
pected amplification product of 161 bp in length.
C. trachomatis genotyping
C. trachomatis genotyping were performed by ompA
gene primers; positive PCR amplification products were
purified, sequenced and analysed with BLAST program
(http://www.ncbi.nlm.nih.gov/BLAST) as previously de-
scribed [20].
HPV detection and characterization
HPV was detected in CS specimens using molecular
assay supported by the Luminex technology (Luminex
Corporation, Austin, TX). HPV genotyping was per-
formed using the type specific E7 polymerase chain reac-
tion bead-based multiplex assay (TS-E7-MPG, IARC,
Lyon, France) as recently described [21]. The detection
limits of the assay ranged from 10 to 1,000 copies of the
viral genomes included in the analysis. In addition, the
β-globin gene was included, as internal positive control
[22]. To analyse a greater number of LR-HPV types,
(HPV-6,-11,-40,-42,-43,-44,-54,-61,-70), the Anyplex™ II
HPV Detection assay (Seegene Inc., Arrow diagnostics,
Italy) was additionally used in according to manufac-
turer’s instructions. A human housekeeping gene was
used as an endogenous internal control, which can en-
sure DNA purification, PCR reaction and specimen
quality (Anyplex™ user manual, Seegene 2012).
Statistical analysis
Chi Square Test was used to compare frequencies of
discrete variables: Fisher Exact Test was applied when
necessary. P value ≤ 0.05 was considered as the threshold
of statistical significance for all tests.
Results
During 2013 year, 1071 cervical swabs from women at
risk for C. trachomatis infection (mean age 35 ± 10 years;
range: from 15 to 72 years) were analysed at the Virology
laboratory of IRCCS-Burlo Garofolo, Trieste, Italy. Ofthese, 829 included Outpatients (mean age 35 ± 10 years),
161 patients from Sexually Transmitted Infection centre
(STI) (mean age 30 ± 10 years) and 81 women from the
Assisted Reproductive Technology (ART) (mean age 37 ±
10 years) clinic. All women were asymptomatic for C. tra-
chomatis and other genital infections at the time of sam-
pling, with the exception of STI women showing
inflammatory symptoms. Moreover, all women were
negative for cytological alterations, in accordance with
Bethesda System 2001 diagnostic criteria [23].
In this study, as showed in Table 1, the overall preva-
lence of C. trachomatis infection was 4.5% (53/1071)
(mean age 35 years). As expected, C. trachomatis preva-
lence, stratified by the different clinical departments
and by age, was found statistically significant higher
(12.4%) in symptomatic women attending the STI cen-
ter, than in asymptomatic women from the other groups
(p < 0.001).
In women with a C. trachomatis infection the overall
prevalence of HPV was high, tested to 60.4% (32/53),
as shown in Table 2. Regarding the distribution of
HPV, the 37.5% (12/32) of the infections were consti-
tuted by a single genotype while the 62.5% (20/32) by
multiple genotypes (from 2 to 8 types), recovered more
frequently in younger women (mean age 24 years)
(Figure 1).
The analysis of HPV genotypes, reassumed in the
Figure 2, showed that HPV-42 and HPV-31 represented
the most frequently detected genotypes, standing at 28%











single multiplen° ofHPV 
HPV genotypes
Figure 1 HPV genotypes distribution detected in C. trachomatis positive women, according to single versus multiple concurrent
infection status. HR: High risk; prHR: Presumable High risk; LR: Low risk.
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infection while the genotypes HPV-6-51-59-66 were de-
tected together in 31% (10/32) of the recovered infections.
In order to characterize the chlamydial phase of in-
fection, the mRNA expression of the Hsp60 gene
showed that the 53% (28/53) of the women with C. tra-
chomatis were suffering from a chronic infection
(Table 3). Of these women (mean age 26 years), the 68%
(19/28) resulted co-infected with HPV. In particular, the
79% (15/19) presented multiple infections and the 21%
(4/19) single infections. Moreover, the level of Ct-Hsp60
expression was found significantly lower (±396 copy/μl)
in women co-infected with HPV compared to women
infected only with C. trachomatis (±862 copies/μl). The
evidence for viable organisms and not just residual
DNA from a previous infection was supported to high








Figure 2 Prevalence of HPV genotypes detected in C. trachomatis co-
LR: Low risk.shown), considering that, the expressed gene should be
linked to the C. trachomatis persistence.
The classification of C. trachomatis serotypes through
the ompA gene amplification and subsequent sequen-
cing, performed in available samples, had revealed a high
frequency of serotype F, independently of chlamydial
status or HPV infection.
Discussion
Several epidemiological studies have stated a positive asso-
ciation between C. trachomatis and HPV-related cervical
diseases. The co-presence of C. trachomatis and HPV was
reported in cervical precancerous lesions, and high levels
of specific IgG antibodies or DNA of C. trachomatis were
recovered in HPV positive patients [6,14,15]. However, the
exact relationship between C. trachomatis and HPV infec-
tion is still not completely understood.n ° of case frequence
otypes 
infected women (n° and%). HR: High risk; prHR: Presumable High risk;
Table 3 RNA expression of the CT-Hsp60 gene in relation
to the presence or absence of HPV infection
CT-Hsp60 RNA
(+) (−)
N°/TOT (%) 28/53 (53) 25/53 (47)
HPV + n° (%) 19/28 (68)* 13/25 (52)
HPV- n° (%) 9/28 (32) 12/25 (48)
*4/19 (21%) HPV single infection and 15/19 (79%) HPV multiple infections.
CT: C. trachomatis; Hsp60: Heat shock protein 60; HPV: Human papillomavirus.
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of HPV DNA-positive infections analysing a large num-
ber of specimens collected as part of routine screening
practices for C. trachomatis prevention. For the first
time, estimates are provided on the prevalence of HPV
infections and about genotype distribution in women
with a chronic C. trachomatis infection; this work has
never been assessed before. Data from our study showed
that the 60.4% of women with a diagnosis of C. tracho-
matis infection and in absence of cervical lesions, re-
sulted co-infected with one or more HPV genotypes. To
note, the 53% of them showed a chronic infection and,
HPV was found more frequently associated (68%) to
this specific chlamydial status. Moreover, a consistent
portion of these women (79%) resulted to be infected
with multiple HPV genotypes. To note, HPV multiple
infections including specific genotypes such as HPV-6-
51-59-66, was reported in the 31% of these women sup-
porting evidence that the presence of one HPV type does
not increase the likelihood of acquiring further infections,
but that, HPV multiple infections might be the result of
the local immune system impairment [8,24-31]. In our
screening population, the median age of women with 2 to
8 HPV genotypes was 24 years, according to recent data
[32,33].
In our series, HPV-31 and HPV-42 represented the
genotypes more frequently detected, testing at 28% and
22%, respectively. The overall prevalence of these ge-
notypes, with a smaller estimated oncogenic poten-
tials than HPV-16, were usually lower in HPV
screening Italian women (13.8% and 0.3%,) [34,35].
While, conversely, HPV-16 (30.7%) [34] was found
only in the 9%.
In the natural history of C. trachomatis, a chronic
infection is referred as a stop in development of
chlamydial cycle, with aberrant bodies formation, and
this state is characterized by high transcriptional
activity [36].
In this study, the expression of Hsp60 gene, a marker
of chronic infection, has been found significantly lower
in HPV co-infected women compared to women in-
fected only with C. trachomatis. Discussion on thisfinding can be merely speculative, suggesting that the
maintenance of a steady-state level of transcription of
Hsp60 gene could favour a balance between the Hsp60
induced pro-inflammatory microenvironment and HPV
coexistence [14].
The chronic inflammation caused by C. trachomatis
increases oxidative stress proteins that seem to trigger
HPV cell entrance, and replication or enhance DNA
breaks that may promote viral integration [9,14,16].
Although it has been suggested that the concomitant
presence of HPV viral oncoproteins during Hsp60
expression may lead to the ability to survive apoptotic
stimuli, uncontrolled proliferation and, finally neoplas-
tic transformation, in this study specific HPV multiple
genotypes were found associated to C. trachomatis
chronic status, independently of the genotypes risk
[37,38].Conclusions
In conclusion, the results of the present investigation
provide evidence for the notion that a high prevalence of
multiple HPV infections has been associated with C. tra-
chomatis chronic infection in young women without cer-
vical lesions. In addition, specific HPV genotypes seem
to be more frequently associated to C. trachomatis. This
data may deserve further consideration, owing to accu-
mulate evidence that the chlamydial chronic status could
contribute to favour specific HPV genotypes represent-
ing possible implications for the prevention of cervical
cancer.
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